人工强制展开的蛋白质反应减少了多个临床前模型的ALS/FTD的疾病特征
Vicente Valenzuela1, Daniela Becerra1, José I Astorga1
1Program of Cellular and Molecular Biology, Biomedical Sciences Institute (ICBM), Universidad de Chile, Santiago, Chile; Biomedical Neuroscience, Faculty of Medicine, Universidad de Chile, Santiago, Chile; FONDAP Center for Geroscience, Brain Health and Metabolism, Santiago, Chile.
概括
通过XBP1s增强未折叠的蛋白质反应 (UPR) 来恢复内质网膜 (ER) 蛋白质稳定性,对治疗肌缩侧面硬化症 (ALS) 和前性痴呆症 (FTD) 显示出有前途. 这种方法在疾病模型中改善了运动功能和生存率.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 肌缩侧面硬化 (ALS) 和前性痴呆 (FTD) 是神经退行性疾病,具有重叠的遗传原因和病理特征,包括蛋白质聚合.
- 缺陷的内等质网膜 (ER) 蛋白质稳定和未展开的蛋白质反应 (UPR) 的低最佳激活是ALS和FTD的常见潜在机制.
- 转录因子X盒结合蛋白1拼接 (XBP1s) 是UPR的关键调节者,对于管理ER压力至关重要.
研究的目的:
- 调查通过XBP1s表达的人工增强UPR是否可以改善ALS和FTD病理.
- 评估针对ER蛋白质稳定作为ALS/FTD频谱障碍的泛治疗策略的治疗潜力.
主要方法:
- 腺相关病毒 (AAV) 用于将活性XBP1s的基因输送到已确定的ALS和FTD动物模型的神经系统中.
- 在接受治疗和对照动物中评估了脊髓组织的运动性能,寿命,蛋白质聚合和蛋白质特征.
- 在疾病模型中诱导实验性ER压力以评估UPR激活水平.
主要成果:
- 在突变SOD1小鼠中,AAV-XBP1s的脑内管内给药改善了运动功能和延长了寿命,伴随着蛋白质聚合的减少.
- 在与TDP-43和C9orf72突变相关的模型中,AAV-XBP1s治疗减轻了疾病进展,这是ALS/FTD的关键遗传驱动因素.
- 蛋白质组分析显示,XBP1s的过度表达增强了蛋白质稳定,并调节了脊髓中的突触和细胞形态蛋白.
结论:
- 通过XBP1s激活UPR来增强ER蛋白质静止,代表了ALS和FTD的可行的治疗策略.
- 针对UPR为各种各样的ALS/FTD疾病提供了潜在的泛治疗方法.
- 通过XBP1s恢复蛋白质稳定可能会抵消蛋白质错折和聚合在神经退行症中的有害影响.
相关概念视频
The Unfolded Protein Response
4.4K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
4.4K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Protein Folding Quality Check in the RER
3.7K
ER is the primary site for the maturation and folding of soluble and transmembrane secretory proteins. The calnexin cycle is a specific chaperone system that folds and assesses the confirmation of N-glycosylated proteins before they can exit the ER lumen. The primary players of this quality check pipeline are the lectins, ER-resident chaperones, and a glucosyl transferase enzyme. In case the calnexin system in the lumen fails to salvage a misfolded protein, it is transported to the cytoplasm...
3.7K


